Get started
Author

Romina Mora Barthelmess

Observed name: Barthelmess, Romina Mora
ORCID: 0000-0003-1384-4483
Observed ORCID: 0000-0003-1384-4483
OpenAlex ID: A5031206745
Hallmarks of Cancer Affected by the MIF Cytokine Family
2023 · Romina Mora Barthelmess, Benoit Stijlemans, et al. · Cancers · 67
PDF
Imaging of tumor-associated macrophage dynamics during immunotherapy using a CD163-specific nanobody-based immunotracer
2024 · Yoline Lauwers, Timo W. M. De Groof, et al. · Proceedings of the National Academy of Sciences · 30
PDF
A few good reasons to use nanobodies for cancer treatment
2023 · Neema Ahishakiye Jumapili, Maida Zivalj, et al. · European Journal of Immunology · 27
PDF
Epigenomic preconditioning of peripheral monocytes determines their transcriptional response to the tumor microenvironment
2025 · Máté Kiss, Laszlo Halasz, et al. · Genome Medicine · 9
PDF
VSIG4‐Expressing Macrophages Contribute to Antiparasitic and Antimetastatic Responses in the Peritoneal Cavity
2025 · Els Lebegge, Daliya Kancheva, et al. · European Journal of Immunology · 5
PDF
Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
2025 · Sana M. Arnouk, Daliya Kancheva, et al. · Cancer Research · 4
PDF
VSIG4 Is Dispensable for Tumor Growth and Metastasis in Murine Colorectal and Breast Cancer Models
2025 · Els Lebegge, Neema Ahishakiye Jumapili, et al. · Cancers · 1
PDF
Figure S9 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
2025 · Sana M. Arnouk, Daliya Kancheva, et al.
PDF
Figure S3 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
2025 · Sana M. Arnouk, Daliya Kancheva, et al.
PDF
Figure S5 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
2025 · Sana M. Arnouk, Daliya Kancheva, et al.
PDF
Figure S14 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
2025 · Sana M. Arnouk, Daliya Kancheva, et al.
PDF
Figure S1 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
2025 · Sana M. Arnouk, Daliya Kancheva, et al.
PDF
Figure S16 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
2025 · Sana M. Arnouk, Daliya Kancheva, et al.
Figure S4 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
2025 · Sana M. Arnouk, Daliya Kancheva, et al.
PDF
Figure S15 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
2025 · Sana M. Arnouk, Daliya Kancheva, et al.
PDF
Figure S11 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
2025 · Sana M. Arnouk, Daliya Kancheva, et al.
PDF
Figure S8 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
2025 · Sana M. Arnouk, Daliya Kancheva, et al.
PDF
Figure S7 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
2025 · Sana M. Arnouk, Daliya Kancheva, et al.
PDF
Figure S10 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
2025 · Sana M. Arnouk, Daliya Kancheva, et al.
PDF
Figure S13 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
2025 · Sana M. Arnouk, Daliya Kancheva, et al.
PDF
Figure S12 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
2025 · Sana M. Arnouk, Daliya Kancheva, et al.
PDF
Figure S6 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
2025 · Sana M. Arnouk, Daliya Kancheva, et al.
PDF
Figure S2 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
2025 · Sana M. Arnouk, Daliya Kancheva, et al.
PDF
Data from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
2025 · Sana M. Arnouk, Daliya Kancheva, et al.
Author response for "VSIG4-Expressing Macrophages Contribute to Antiparasitic and Antimetastatic Responses in the Peritoneal Cavity"
2025 · Lebegge, Els, Kancheva, Daliya, et al.
Works count: 27
Citation count: 143
H-index: 5
I10-index: 3
Year
Topic
Type